Tubulis
Tubulis
Develops antibody-drug conjugates (ADCs) for targeted cancer therapy.
About
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline. Teams look it up for BiTech, MedTech, HealthTech.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
